Moxifloxacin hydrochloride ( DrugBank: Moxifloxacin )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	1
299	嚢胞性線維症	1

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04821063 (ClinicalTrials.gov)	April 13, 2021	26/3/2021	Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval	A Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval in Healthy Male and Female Subjects	Duchenne and Becker Muscular Dystrophy;Polycytemia Vera	Drug: ITF2357 10 mg/mL;Drug: Placebo;Drug: Moxifloxacin Hydrochloride	Italfarmaco	NULL	Completed	18 Years	55 Years	All	31	Phase 1	Canada

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910415 (ClinicalTrials.gov)	June 2013	19/7/2013	Phase 1, QT/QTC Interval Study in Healthy Subjects	A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects	Cystic Fibrosis	Drug: Lumacaftor;Drug: Lumacaftor Placebo;Drug: Ivacaftor;Drug: Ivacaftor Placebo;Drug: moxifloxacin hydrochloride	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	55 Years	Both	200	Phase 1	Netherlands